Investors purchased shares of Medtronic (NYSE:MDT) on weakness during trading on Tuesday. $172.27 million flowed into the stock on the tick-up and $43.81 million flowed out of the stock on the tick-down, for a money net flow of $128.46 million into the stock. Of all companies tracked, Medtronic had the 7th highest net in-flow for the day. Medtronic traded down ($0.65) for the day and closed at $79.37
Several research analysts recently commented on the stock. Oppenheimer set a $94.00 price target on shares of Medtronic and gave the company a “buy” rating in a report on Friday, January 19th. Morgan Stanley raised their price target on shares of Medtronic from $91.00 to $95.00 and gave the company an “equal weight” rating in a report on Monday, February 5th. Evercore ISI began coverage on shares of Medtronic in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $92.50 price objective on the stock. TheStreet lowered shares of Medtronic from a “b” rating to a “c+” rating in a research note on Tuesday, February 20th. Finally, Citigroup reiterated a “buy” rating and set a $93.00 price objective (down previously from $100.00) on shares of Medtronic in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have issued a buy rating to the stock. Medtronic presently has an average rating of “Buy” and a consensus target price of $91.24.
The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.09 and a current ratio of 2.43. The stock has a market capitalization of $107,575.96, a price-to-earnings ratio of 17.27, a P/E/G ratio of 2.36 and a beta of 0.94.
The business also recently declared a quarterly dividend, which was paid on Friday, April 13th. Stockholders of record on Friday, March 23rd were given a dividend of $0.46 per share. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.30%. The ex-dividend date of this dividend was Thursday, March 22nd. Medtronic’s payout ratio is currently 40.00%.
In other Medtronic news, Director James T. Lenehan sold 1,306 shares of Medtronic stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $83.56, for a total value of $109,129.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Carol A. Surface sold 24,479 shares of Medtronic stock in a transaction on Monday, March 5th. The stock was sold at an average price of $78.18, for a total transaction of $1,913,768.22. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. We Are One Seven LLC acquired a new position in shares of Medtronic during the fourth quarter valued at $104,000. BB&T Investment Services Inc. boosted its holdings in shares of Medtronic by 147.6% during the fourth quarter. BB&T Investment Services Inc. now owns 1,518 shares of the medical technology company’s stock valued at $126,000 after acquiring an additional 905 shares during the period. Barrett Asset Management LLC boosted its holdings in shares of Medtronic by 856.0% during the fourth quarter. Barrett Asset Management LLC now owns 1,826 shares of the medical technology company’s stock valued at $147,000 after acquiring an additional 1,635 shares during the period. SevenBridge Financial Group LLC boosted its holdings in shares of Medtronic by 76.2% during the third quarter. SevenBridge Financial Group LLC now owns 2,197 shares of the medical technology company’s stock valued at $171,000 after acquiring an additional 950 shares during the period. Finally, Proficio Capital Partners LLC boosted its holdings in shares of Medtronic by 51.2% during the fourth quarter. Proficio Capital Partners LLC now owns 2,201 shares of the medical technology company’s stock valued at $178,000 after acquiring an additional 745 shares during the period. 81.76% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://stocknewstimes.com/2018/04/26/traders-buy-medtronic-mdt-on-weakness.html.
Medtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company's Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.